A Phase 3b Study of Participant Experience on Povetacicept Administered Via Autoinjector as Compared to Sibeprenlimab Administered Via Prefilled Syringe (clinicaltrials.gov) - Oct 23, 2026 - P3 | N=40 | Not yet recruiting | Sponsor: Vertex Pharmaceuticals Incorporated
New P3 trial • Glomerulonephritis • IgA Nephropathy • Renal Disease
|